M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta BioSpaceJohnson & Johnson secured rights to prizlon-cel in 2023 for $245 million upfront.OncologyRead full story pharminent August 17, 2026 (Last updated: August 21, 2026) BioSpace Johnson & Johnson secured rights to prizlon-cel in 2023 for $245 million upfront. Oncology Read full story Post navigation Previous: Novo Nordisk and AWS form AI partnership to speed drug discoveryNext: AstraZeneca Claims Dual Lung Cancer Phase 3 Wins, but Bispecific Failure Steals the Headline Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026